Lerkanidipin Actavis

Lercanidipine Hydrochloride, the active ingredient in Lerkanidipin Actavis, is a calcium channel blocker presented as an oral tablet for oral use. It lowers elevated blood pressure in adults with essential hypertension and is prescribed as part of a comprehensive antihypertensive regimen. It is indicated for patients who require consistent blood pressure control and may be combined with other antihypertensive agents as needed.

GNH USA supplies Lerkanidipin Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring reliable quality, regulatory compliance and on‑time delivery across multiple markets.

Lercanidipine is used to treat hypertension, a condition characterized by elevated arterial pressure.

- Essential hypertension: reduces systolic and diastolic blood pressure in patients with primary high blood pressure. - Isolated systolic hypertension: lowers elevated systolic pressure, particularly in elderly patients. - Hypertension in patients with cardiovascular risk factors: contributes to overall blood pressure control as part of combination therapy.

Lercanidipine may cause a range of adverse reactions, which are generally classified by frequency.

Common Side Effects: - Headache: mild to moderate headache occurring shortly after dose initiation. - Flushing: transient warmth and redness of the face or neck. - Peripheral edema: swelling of the ankles or lower legs, especially after prolonged use. - Dizziness: sensation of light‑headedness, often related to blood pressure reduction. - Tachycardia: increased heart rate in some patients.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure that may cause fainting. - Angioedema: rapid swelling of the face, lips, tongue, or throat requiring emergency care. - Hepatic dysfunction: abnormal liver enzyme elevations indicating possible liver injury. - Myocardial infarction: rare occurrence of heart attack, particularly in patients with pre‑existing coronary disease. - Allergic reactions: rash, pruritus, or anaphylaxis in susceptible individuals.

Before initiating therapy, clinicians should consider several safety aspects. - Blood pressure monitoring: regularly assess to avoid excessive hypotension. - Hepatic impairment: use with caution in patients with liver dysfunction, adjusting dose if necessary. - Elderly patients: start at the lowest effective dose and monitor for edema. - Concomitant antihypertensives: evaluate for additive blood pressure‑lowering effects. - Pregnancy and lactation: avoid unless clearly needed, as safety data are limited. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations and risk of hypotension. - Concurrent use with other potent vasodilators: can cause severe blood pressure drops.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Non‑dihydropyridine calcium channel blockers: may enhance bradycardia or AV‑block risk. - Grapefruit juice: can elevate lercanidipine levels, requiring dose adjustment. - NSAIDs: may attenuate antihypertensive response, necessitating blood pressure monitoring.